Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Ying Huang Analyst Performance

Analyst at Bank of America

Ying Huang is a stock analyst at Bank of America in the medical sector, covering 7 publicly traded companies. Over the past year, Ying Huang has issued 1 stock ratings, including and buy recommendations. While full access to Ying Huang's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Ying Huang's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
28 Last 11 Years
Buy Recommendations
46.43% 13 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy46.4%13 ratings
Hold32.1%9 ratings
Sell21.4%6 ratings

Out of 28 total stock ratings issued by Ying Huang at Bank of America, the majority (46.4%) have been Buy recommendations, followed by 32.1% Hold and 21.4% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
85.7% of companies on NASDAQ
6 companies
NYSE
14.3% of companies on NYSE
1 company

Ying Huang, an analyst at Bank of America, currently covers 7 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Ying Huang of Bank of America specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
85.7%
BIOTECHNOLOGY
1 company
14.3%

Ying Huang's Ratings History at Bank of America

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
3/10/2026Boost Price Target$504.75$598.00Buy
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
3/31/2025Boost Price Target$492.69$567.00Buy